Cargando…
Combined HP (13)C Pyruvate and (13)C-Glucose Fluxomic as a Potential Marker of Response to Targeted Therapies in YUMM1.7 Melanoma Xenografts
A vast majority of BRAF V600E mutated melanoma patients will develop resistance to combined BRAF/MEK inhibition after initial clinical response. Resistance to targeted therapy is described to be accompanied by specific metabolic changes in melanoma. The aim of this work was to evaluate metabolic ima...
Autores principales: | Farah, Chantale, Neveu, Marie-Aline, Yelek, Caner, Bouzin, Caroline, Gallez, Bernard, Baurain, Jean-François, Mignion, Lionel, Jordan, Bénédicte F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945537/ https://www.ncbi.nlm.nih.gov/pubmed/35327519 http://dx.doi.org/10.3390/biomedicines10030717 |
Ejemplares similares
-
Hyperpolarized (13)C-Pyruvate to Assess Response to Anti-PD1 Immune Checkpoint Inhibition in YUMMER 1.7 Melanoma Xenografts
por: Farah, Chantale, et al.
Publicado: (2023) -
Metabolic imaging using hyperpolarized (13)C‐pyruvate to assess sensitivity to the B‐Raf inhibitor vemurafenib in melanoma cells and xenografts
por: Acciardo, Stefania, et al.
Publicado: (2019) -
Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018) -
Fluxomers: a new approach for (13)C metabolic flux analysis
por: Srour, Orr, et al.
Publicado: (2011) -
Tumor Metabolism Is Affected by Obesity in Preclinical Models of Triple-Negative Breast Cancer
por: Yelek, Caner, et al.
Publicado: (2022)